Mechanism of tissue-selective drug action in the cardiovascular system

Molecular Interventions

Volumn 5, Issue 2, 2005, Pages 84-93

  Barrett, Terrance D ^a   Triggle, David J ^b   Walker, Michael J A ^c   Maurice, Donald H ^d  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHALENEACETIC ACID 2 MORPHOLINOCYCLOHEXYL ESTER; 1,4 DIHYDROPYRIDINE; 4 BROMOPHENYLACETIC ACID 2 MORPHOLINOCYCLOHEXYL ESTER; AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; CYCLIC GMP; DILTIAZEM; FELODIPINE; ISRADIPINE; LACIDIPINE; LIDOCAINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL;

CALCIUM MOBILIZATION; CARDIOVASCULAR SYSTEM; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ERECTILE DYSFUNCTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN GENOME; HYPERTENSION; MODEL; NONHUMAN; REVIEW; TREATMENT INDICATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; BINDING SITES; CALCIUM CHANNELS; CARDIOVASCULAR SYSTEM; CHEMISTRY, PHARMACEUTICAL; ELECTROPHYSIOLOGY; HUMANS; HYPERTENSION; IMPOTENCE; ISCHEMIA; MALE; MODELS, ANATOMIC; MODELS, BIOLOGICAL; MYOCARDIUM; NIFEDIPINE; PHOSPHODIESTERASE INHIBITORS; VERAPAMIL;

EID: 17844400539     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.5.2.6     Document Type: Review

References (29)

1. Black, J.W. Pharmacology: Analysis and exploration. Br. Med. J. 293, 252-255 (1986).
2. Furchgott, R.F. The use of haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res. 3, 21-55, (1966).
3. Limbird, L.E. The receptor concept: A continuing evolution. Mol. Interv. 4, 326-336 (2004).
4. Triggle, D.J. Mechanisms of action of calcium antagonists, in Calcium Antagonists in Clinical Medicine (Epstein, M. ed)pp 1-29, Hanley and Belfus, Philadelphia, (2002).
5. Triggle,D.J. Pharmacology of CaV1 (L-type ) channels, in Calcium Channel Pharmacology (McDonough, S., ed) pp 21-72, Kluwer Academic Press, Boston, (2004).
6. Catterall, W.A. Structure and regulation of voltage-gated calcium channels. Ann. Rev. Cell Dev. Biol. 16, 521-555, (2000).
7. Welling, A. Ludwig, A. Zimmer, S., Klugbauer, N., Flockerzi, V., and Hofmann, F. Alternatively spliced IS6 segments of the _1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle. Circ. Res. 81, 526-532, (1997).
8. Lipscombe, D. and Castiglioni, A.J. Alternative splicing of voltage-gated calcium channels, in Calcium Channel Pharmacology (McDonough, S. ed) pp 369-410, Kluwer Academic, New York, (2004).
9. Hondeghem, L.M. and Katzung, B.G. Antiarrhythmic agents: The modulated receptor mechanism of action of sodium and calcium channel blocking drugs. Ann. Rev. Pharmacol. 24, 387-423, (1985).
10. Sun J.P. and Triggle, D.J. Calcium channel antagonists: Cardiovascular selectivity of action. J. Pharmacol. Exp. Therap. 274, 419-428, (1995).
11. Kleinbloesem, C.H., van Brummelen, P., Danhof, M. et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin. Pharmacol. Therap. 41, 26-30, (1987).
12. van Den Kerchoff, W. and Drewes, I.R. Transfer of nimodipine and another calcium antagonist across the regional blood brain barrier and their regional distribution in vivo, in The Diagnosis and Treatment of Senile Dementia (Bergener, M. and Reisberg, L. eds) Springer-Verlag, Berlin, (1989).
13. Mori, Y. Itsukahi, Y., Nishida, M., and Oka, H. Calcium channel mutations and associated diseases, in Calcium Channel Pharmacology (McDonough, S. ed) pp 303-330, Kluwer Academic, Boston, (2004).
14. Walker, M.J.A. Antiarrhythmic drug development - illusion and disillusion. Drug Dev. Res. 55, 1-2, (2002).
15. Echt D.S., Liebson, P.R., Mitchell. L.B. et al. Mortality and morbidity in patients receiving encainide, flecainide or pacebo. The cardiac arrhythmia supression trial. N. Engl. J. Med. 324, 781-788 (1991).
16. Beatch, G.N., Barrett, T.D., Plouvier, B., Jung, G., Wall, R.A., Zolotoy, A., and Walker M.J.A. Ventricular fibrillation, an uncontrolled arrhythmia seeking new targets. Drug Dev. Res. 55 , 45-52, (2002).
17. Bain, A.I., Barrett, T.D., Beatch, G.N. et al. Better antiarrhythmics? Development of antiarrhythmic drugs selective for ischaemia-dependent arrhythmias. Drug Dev. Res. 42, 198-210, (1997).
18. Yong, S.L., Xu, R., McLarnon, J.G., Zolotoy, A.B., Beatch, G.N., and Walker, M.J.A. RSD1000: A novel atiarrhythmic agent with increased potency under acidic and high-potassium conditions. J. Pharmacol. Exp. Ther. 289, 236-244, (1999).
19. Barrett, T.D., Hayes, E.S., Yong, S.L., Zolotoy, A.B., Abraham, S., and Walker, M.J.A. Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats. Eur. J. Pharmac. 398, 365-374, (2000).
20. Saenz de Tejada, I., Gonzales Cadavid, N., Heaton, J. et al. Anatomy, physiology and pathophysiology of erectile function, in Erectile Dysfunction (Jardin, A. and Wagner, G., eds) pp 65-102, Health Publication Ltd, Plymouth (2000).
21. Nitahara, K.S. and Lue, T.F. Microscopic anatomy of the penis, in Erectile Dysfunction (Carson, C.C., Kirby, R., and Goldstein, R. eds) ISIS Medical Media, Oxford,, pp31-42 (1999).
22. Maurice, D.H. Cardiovascular implications in the use of PDE5 inhibitor therapy. Int. J. Impot. Res. 16, S20-23 (2004).
23. Maurice, D.H., Palmer, D., Tilley, D.G., Dunkerley, H.A., Netherton, S.J., Raymond, D.R., Elbatarny, H.S., and Jimmo, S.L. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64, 533-546. (2003).
24. Corbin, J.D. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int. J. Impot. Res. 16, S4-7. (2004).
25. Kotera, J., Francis, S.H., Grimes, K.A., Rouse, A., Blount, M.A., and Corbin, J.D. Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. Front. Biosci. 9, 378-386 (2004).
26. Francis, S.H., Bessay, E.P., Kotera, J., Grimes, K.A., Liu, L., Thompson, W.J., and Corbin, J.D. (2002) Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J. Biol. Chem. 277, 47581-47587 (2002).
27. Rybalkin, S.D., Rybalkina, I.G., Shimizu-Albergine, M., Tang, X.B., and Beavo, J.A. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. 22, 469-478 (2003).
28. Rybalkin, S.D., Rybalkina, I.G., Feil, R., Hofmann, F., and Beavo, J.A. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem. 277, 3310-3317 (2002).
29. Godfraind, T., Salomone, S., Dessy, C., Verhelst, B., Dion, R., and Schoevaerts, J.C. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacol. 20, S34-S41 (1992).